DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ravulizumab
Ravulizumab
Specialty Pipeline Monthly Update
Pharmaceuticals and Medical Devices Safety Information No
CHMP Agenda of the 19-22 April 2021 Meeting
New Indications & Dosage Froms for Existing Drugs
MAXIMUM DOSAGE & FREQUENCY Policy Number: CSLA2020D0034X Effective Date: TBD
Infusion Site of Care and Specialty Pharmacy
Soluble Ligands As Drug Targets
Overview of Planned Or Ongoing Studies of Drugs for the Treatment of COVID-19
Place of Service for Medical Infusions “Notification” POLICY EFFECTIVE OCTOBER 1, 2021
Medication Matters Confirmed COVID-19 Pneumonia
Payor Strategies to Drive Biosimilars Access and Savings Grx+Biosims Conference 2019
John Hopkins Medicine Medicare Advantage Novologix Prior
Formoscreen® Antibody Formulation Screen
Pharmaceuticals and Medical Devices Safety Information No
Outpatient Drug Services Handbook
B Cells and Antibodies As Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders
Stembook 2018.Pdf
(CHMP) Agenda for the Meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Top View
Horizon Scanning Status Report December 2020
Injections: Drugs NR Policy
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Codes Drug Name J3262 Actemra (Tocilizumab) J9057 Aliqopa
(INN) for Biological and Biotechnological Substances
Medical Policy Update Bulletin
New Drugs Approved in FY 2019
A61K9/51 (2006.01) — with International Search Report (Art
HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use ULTOMIRIS Safely and Effectively
CHMP Agenda of the 20-23 July 2020 Meeting
Complement Inhibitors
FEP 5 Tier Rx Drug Formulary (607) Standard Option
2021 Medicare Prior Authorization List Part B Appendix Effective August 1
C9050 Injection, Emapalumab-Lzsg, 1 Mg C9122
Approved Site of Care List
Ravulizumab for Atypical Haemolytic Uremic Syndrome
Fc-Engineering for Modulated Effector Functions—Improving Antibodies
Maximum Dosage and Frequency – Community Plan Medical Benefit
Moving up with the Monoclonals
Specialty Pipeline MONTHLY UPDATE
Policy Drug(S) Brief Description of Policy Change UM ONC 1038 Emend (Aprepitant Oral Or Add Exclusion Criteria: 1
Essential Plan Authorization Grid FIDELIS CARE AUTHORIZATION
Novartis R&D
Mandatory Specialty Drug List
Complement Inhibitors (Soliris® & Ultomiris®)
Drug Prior Authorization Requirements (Office, Home Or Outpatient Setting) Effective January 1, 2021*
December 2019
Ravulizumab Targets (1) Biointeractions (1)
MAXIMUM DOSAGE Policy Number: CSLA2020D0034W Effective Date:TBD
Specialty Pipeline MONTHLY UPDATE May 2021
List Item Minutes of the CHMP Meeting 27-29 May 2019 (PDF
P&T Committee Meeting Minutes Commercial
Biosimilars – 2019 Year in Review
NEW--Npf-MASTER LIST.Xlsx
Codes Drug Name J3262 Actemra
Analyzing and Validating the Prognostic Value and Immune Microenvironment of Clear Cell Renal Cell Carcinoma
Evaluation of Non-Clinical Requirements for Medicinal
Bjh.16711.Pdf
Clinical Trials
Maximum Dosage and Frequency – Commercial Medical Benefit Drug
Drugs Billed at Maximum Allowable Cost (MAC)
Ultomiris (Ravulizumab)
Patient Self-Reporting in the Evaluation of Cancer Drug Tolerability
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Antibodies to Watch in 2018